| Code | CSB-RA023986MB11HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to HS629, targeting TNFSF11 (Tumor Necrosis Factor Superfamily Member 11), also known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). TNFSF11 is a critical cytokine that regulates bone metabolism by promoting osteoclast differentiation, activation, and survival. This protein plays a central role in maintaining skeletal integrity and calcium homeostasis. Dysregulation of TNFSF11 signaling is implicated in various pathological conditions, including osteoporosis, rheumatoid arthritis, bone metastases, and multiple myeloma. The RANKL/RANK/OPG pathway represents a fundamental mechanism in bone remodeling and immune system regulation.
HS629, a biosimilar drug of denosumab, is a fully humanized monoclonal antibody against RANKL. It blocks the binding of RANKL to its receptor RANK, strongly inhibiting the generation, activation and function of osteoclasts, thereby significantly reducing bone resorption and increasing bone density. It has been approved for the treatment of osteoporosis in postmenopausal women with a high risk of fractures, as well as for the prevention of bone-related events in patients with bone metastases from solid tumors and multiple myeloma. This biosimilar antibody provides researchers with a reliable tool for studying TNFSF11 biology, exploring osteoclast-mediated bone resorption mechanisms, and investigating potential therapeutic interventions for skeletal and metabolic diseases. It supports various experimental approaches in cell biology, immunology, and translational research focused on bone-related pathologies.
There are currently no reviews for this product.